CN100408594C - Lonicera macranthoides active total saponin extract and its preparing method and use - Google Patents
Lonicera macranthoides active total saponin extract and its preparing method and use Download PDFInfo
- Publication number
- CN100408594C CN100408594C CNB2006100392944A CN200610039294A CN100408594C CN 100408594 C CN100408594 C CN 100408594C CN B2006100392944 A CNB2006100392944 A CN B2006100392944A CN 200610039294 A CN200610039294 A CN 200610039294A CN 100408594 C CN100408594 C CN 100408594C
- Authority
- CN
- China
- Prior art keywords
- extract
- total saponin
- active
- active total
- saponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930182490 saponin Natural products 0.000 title claims abstract description 85
- 150000007949 saponins Chemical class 0.000 title claims abstract description 85
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 79
- 239000000284 extract Substances 0.000 title claims abstract description 58
- 241001170076 Lonicera macranthoides Species 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001556 precipitation Methods 0.000 claims abstract description 9
- 238000003810 ethyl acetate extraction Methods 0.000 claims abstract description 6
- 229920005989 resin Polymers 0.000 claims abstract description 6
- 239000011347 resin Substances 0.000 claims abstract description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004952 Polyamide Substances 0.000 claims abstract description 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- 229920002647 polyamide Polymers 0.000 claims abstract description 4
- 239000002798 polar solvent Substances 0.000 claims abstract description 3
- 238000000638 solvent extraction Methods 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 241001570521 Lonicera periclymenum Species 0.000 claims description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 5
- KPDVIKCSTOVVEA-KZFFKTSUSA-N (4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-4-[(2S,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H](OC[C@H](O)[C@@H]2O)O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@]6(CCC(C)(C)C[C@H]6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)O[C@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KPDVIKCSTOVVEA-KZFFKTSUSA-N 0.000 claims description 4
- AMXYFWUYMQOLRN-BHGPNLNISA-N (4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-10-[(2s,3r,4s,5s)-3-[(2s,3r,4r,5s,6s)-3,5-dihydroxy-6-methyl-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1, Chemical compound O([C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H](OC[C@H](O)[C@@H]2O)O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@]6(CCC(C)(C)C[C@H]6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)O[C@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMXYFWUYMQOLRN-BHGPNLNISA-N 0.000 claims description 4
- ORIMHMILXLTJPC-UHFFFAOYSA-N Macranthoside A Natural products OC1C(O)C(C)OC(OC2C(C(OCC3(C)C4C(C5C(C6(CCC7(CCC(C)(C)CC7C6=CC5)C(O)=O)C)(C)CC4)(C)CCC3O)OC(CO)C2O)O)C1OC1OCC(O)C(O)C1O ORIMHMILXLTJPC-UHFFFAOYSA-N 0.000 claims description 4
- ZLIROJWQOROKCU-UHFFFAOYSA-N Macranthoside B Natural products CC1OC(OC2C(O)C(CO)OC(OC3C(O)C(O)C(OCC4(C)C(O)CCC5(C)C4CCC6(C)C5CC=C7C8CC(C)(C)CCC8(CCC67C)C(=O)O)OC3CO)C2O)C(OC9OCC(O)C(O)C9O)C(O)C1O ZLIROJWQOROKCU-UHFFFAOYSA-N 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 abstract description 78
- 206010028980 Neoplasm Diseases 0.000 abstract description 21
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 10
- 201000005202 lung cancer Diseases 0.000 abstract description 10
- 208000020816 lung neoplasm Diseases 0.000 abstract description 10
- 201000007270 liver cancer Diseases 0.000 abstract description 8
- 208000014018 liver neoplasm Diseases 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000001472 cytotoxic effect Effects 0.000 abstract description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 abstract 1
- 238000005119 centrifugation Methods 0.000 abstract 1
- 238000004440 column chromatography Methods 0.000 abstract 1
- 238000004042 decolorization Methods 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 238000002481 ethanol extraction Methods 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 description 27
- 230000007062 hydrolysis Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 239000007788 liquid Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003513 alkali Substances 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- -1 electuary Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 description 1
- BDXJANJAHYKTMI-UHFFFAOYSA-N 2,3,4,5-tetramethyl-1h-pyrrole Chemical class CC=1NC(C)=C(C)C=1C BDXJANJAHYKTMI-UHFFFAOYSA-N 0.000 description 1
- ASFAFOSQXBRFMV-LJQANCHMSA-N 3-n-(2-benzyl-1,3-dihydroxypropan-2-yl)-1-n-[(1r)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]benzene-1,3-dicarboxamide Chemical compound N([C@H](C)C=1C=CC(F)=CC=1)C(=O)C(C=1)=CC(N(C)S(C)(=O)=O)=CC=1C(=O)NC(CO)(CO)CC1=CC=CC=C1 ASFAFOSQXBRFMV-LJQANCHMSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000729170 Dipsacus asper Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- 241000100289 Lonicera confusa Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 description 1
- 101150107276 hpd-1 gene Proteins 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical compound CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- OILHVNROWDFZDW-UHFFFAOYSA-N prosapogenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C=O)C5CCC34C)C2C1)C(=O)O OILHVNROWDFZDW-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an active total saponin extract of lonicera macranthoides hand-mazz, a preparation method and the application thereof. The extract is active total saponins of onicera macranthoides hand-mazz; the preparation method comprises 50 to 90%Vol ethanol extraction, low polar solvent extraction, ethyl acetate extraction, alkaline hydrolysis, propanone precipitation, centrifugation, macroporous resin or polyamide column chromatography and active carbon decolorization; then, active total saponins of onicera macranthoides hand-mazz are obtained. By using the extraction process and the method of the present invention, the yield and the purity of obtained effective components are high; the pharmacology, drug effect and effective components of active total saponins of onicera macranthoides hand-mazz and the content of the effective components are determined so that effective dose can be easily mastered. Effective dose of effective components obtained by using the method of the present invention have cytotoxic activity on in vitro cultured human cancer cell strains and inhibiting effect on mouse liver cancer H22 solid tumors and Lewis lung cancer solid tumors.
Description
Technical field
The present invention relates to Lonicera macranthoides active total saponin extract and preparation method thereof, and the application of this active total saponin in preparation treatment cancer drug.In particular, the present invention relates to comprise in the largeflower-like honeysuckle flower flower and alabastrum composition that contains antitumour activity sugar chain structure saponin(e and preparation method thereof, undertaken by the hydrolysis of total saponins elder generation is separated to wait again.Thus obtained extract is directly become to be grouped into by activated saponin, and main saponin constituent ratio is clear and definite, is easy to grasp its effective dose, and it is safer, more stable to be used for preparation treatment cancer drug.
Background technology
Largeflower-like honeysuckle flower (Lonicera macranthoides Hand.-Mazz.) is a Caprifoliaceae Caprifoliaceae woodbine, and 2005 editions Pharmacopoeias of People's Republic of China record, and list under the Lonicera confusa DC. item.Woodbine contains a large amount of saponin(es, is mainly ivy type and oleanolic acid type saponin(e.Hederagenin and oleanolic acid type saponin(e have and protect the liver (Shi Jingzhen etc.; several compositions of Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms and largeflower-like honeysuckle flower are to the provide protection of large and small mouse chemical damage; CHINA JOURNAL OF CHINESE MATERIA MEDICA; 1999; 24 (6): 363-364), anticancer (Cytotoxic saponins from the root of Dipsacus asper Wall.Arch Pharm Res.2005,28 (9): 1053-6.) activity.In the separation of Jiangsu Province Chinese Academy of Sciences medicinal plants study development centre main saponin component in to the largeflower-like honeysuckle flower flower and alabastrum, two main saponin components have been obtained, clear and definite composition and the character and the purposes of main saponin component in the largeflower-like honeysuckle flower.The present invention takes to separate after the basic hydrolysis, has both simplified processing step, is fit to industrial mass production, has improved the yield of activated saponin again greatly, and the antitumour activity of the Lonicera macranthoides active total saponin extract that obtains thus compares not hydrolysis total saponins height.
Summary of the invention
Technical problem to be solved by this invention is, providing a kind of the extraction with Lonicera macranthoides active total saponin from the largeflower-like honeysuckle flower flower and alabastrum is the composition of main reactive site and the preparation method of said composition, make preparation raw material (active total saponin) yield and purity height, technology is simple and easy to do, is suitable for suitability for industrialized production.
The technical problem that the present invention further will solve is that providing with the Lonicera macranthoides active total saponin is the medicinal use that efficient part prepares medicine.
The technical solution adopted in the present invention is as follows:
The present invention relates to a kind of Lonicera macranthoides active total saponin extract, main reactive site active total saponin content is 50%-90% in the extract, and contained saponin component meets:
R
3＝H，OH
R
2＝H
R
1=H, sugar chain, wherein main contained saponin(e and their weight ratio is: Macranthoside B: Macranthoside A=12～6: 1.
Lonicera macranthoides active total saponin extract of the present invention is the extract that obtains by following method: the largeflower-like honeysuckle flower flower and alabastrum, with concentration is the extraction using alcohol of 50%-90%, reclaim solvent, use sherwood oil, gasoline, the extraction of low polar solvents such as benzene, water layer is used ethyl acetate extraction again, water layer reclaims solvent to concentrated extract, add 1%-10%NaOH or KOH solution, degraded 2-4 hour down for 40-100 ℃, cold back adds acetone precipitation, and is centrifugal, and centrifugal gained precipitation washes with water to neutrality, with rare alcohol dissolving, the adjusting pH value is 4-7, last macroporous resin column (HP20, D101, AB-8, HPD100, HPD300 etc.) or polyamide column, first water and 20% washing with alcohol post, use the 30%-90% ethanol elution again, collect elutriant, add the medical active carbon decoloring of 3%-5%, filter, concentrate drying promptly gets Lonicera macranthoides active total saponin.
The said Lonicera macranthoides active total saponin extract of the present invention is meant through aforesaid method and extracts the efficient part that obtains.
Lonicera macranthoides active total saponin extract of the present invention proves to have antitumor action through pharmacology, pharmacodynamics and a large amount of animal experiment studies; In experiment in vitro, significantly suppress people's liver cancer HepG
2Cell and people's lung cancer A549 cell propagation; In vivo in the experiment, to H
22Liver cancer cell tumor-bearing mice and Lewis lung cancer cell tumor-bearing mice can suppress growth of tumor, increase tumor-bearing mice immunizing power and lifetime.Ingredient is clear and definite, and dosage is easy to grasp control, therefore can use in the medicine of preparation treatment cancer.
Extract Lonicera macranthoides active total saponin of the present invention can be prepared into tablet, capsule, granule, electuary, powder, pill, oral liquid, syrup, suspensoid, sprays, solution, decoction, gelifying agent, creme, ointment, drops etc.In above-mentioned preparation, the extract of the present invention of effective dose can be separately or with pharmacy acceptable carrier still: composition mixtures such as vehicle, disintegrating agent, lubricant, tinting material.
Embodiment
The saponin component that embodiment one largeflower-like honeysuckle flower bud water section obtains
The largeflower-like honeysuckle flower dry flower, 90% alcohol reflux three times, united extraction liquid, use sherwood oil, ethyl acetate extraction successively, macroporous resin column on the remaining water liquid, through the water-ethanol gradient elution, reversed-phase column purifying decolouring repeatedly obtains two main saponin components, and structure all contains antitumour activity unit.
Two saponin(es are respectively:
Macranthoside B (A), i.e. 3-O-β-D-glucopyranosyl (1-4)-β-D-glucopyranosyl (1-3)-α-L-rhamnopyranosyl (1-2)-α-L-arabopyranose base-hederagenin;
Macranthoside A (B), i.e. 3-O-β-D-glucopyranosyl (1-3)-α-L-rhamnopyranosyl (1-2)-α-L-arabopyranose base-hederagenin;
The assay of saponin(e
1. instrument and reagent
High performance liquid chromatograph Aglient 1100 series, quaternary pump, automatic sampler, detector: Alltech ELSD2000 (Alltech, Deerfield, IL, USA), chromatographic column: Aglient Zorbax SB-C
18Post (150 * 4.6mm, 5.0 μ m), acetonitrile is a chromatographically pure, phosphoric acid is analytical pure.
2. chromatographic condition
Moving phase: 0-10min, acetonitrile: 0.5% phosphoric acid solution is kept ratio (29: 71), 10-25min, the moving phase ratio changes to (46: 54) by (29: 71) are linear, 25-30min, moving phase is kept ratio (46: 54).ELSD manages temperature: 106 ℃.Nitrogen flow rate: 2.6L/min.
3. the preparation of reference substance solution
Accurate respectively Macranthoside B and the Macranthoside A reference substance that takes by weighing through the Vanadium Pentoxide in FLAKES dried overnight respectively adds methyl alcohol and makes the solution that every 1ml contains 0.03mg respectively, solution in contrast.
4. sample determination
Get the about 20mg of powder in this product (get in addition simultaneously this product powder measure moisture), accurately claim surely, put in the apparatus,Soxhlet's, add methanol eddy and extracted 4 hours, put cold after, be transferred in the 100ml volumetric flask, methanol constant volume promptly.Each sample detects through high performance liquid phase, and the content ratio that calculates two kinds of prosapogenins is 12～6: 1, sees embodiment three to ten for details.
Provide 8 embodiments that extract Lonicera macranthoides active total saponin by the preparation method of aforementioned techniques scheme below, see following table for details:
Embodiment two
| Material | Extract concentration | Extraction liquid | Alkali concn | Hydrolysis temperature | Hydrolysis time | PH value | Adsorption column | Active C | Yield | Total saponin content | The saponin(e ratio |
| Bud | 50％ | Sherwood oil | 1％ | 40℃ | 2 hours | 6 | HP-2 0 | 3％ | 1.4％ | 88％ | 12∶1 |
Embodiment three
| Material | Extract concentration | Extraction liquid | Alkali concn | Hydrolysis temperature | Hydrolysis time | PH value | Adsorption column | Active C | Yield | Total saponin content | The saponin(e ratio |
| Flower | 60％ | Gasoline | 3％ | 60℃ | 3 hours | 7 | HP-2 0 | 4％ | 1.4％ | 72％ | 10.4∶ 1 |
Embodiment four
| Material | Extract concentration | Extraction liquid | Alkali concn | Hydrolysis temperature | Hydrolysis time | PH value | Adsorption column | Active C | Yield | Total saponin content | The saponin(e ratio |
| Bud | 70％ | Sherwood oil | 4％ | 60℃ | 2 hours | 6 | D 101 | 3％ | 1.8％ | 80％ | 8.2∶1 |
Embodiment five
| Material | Extract concentration | Extraction liquid | Alkali concn | Hydrolysis temperature | Hydrolysis time | PH value | Adsorption column | Active C | Yield | Total saponin content | The saponin(e ratio |
| Flower | 80％ | Gasoline | 5％ | 80℃ | 4 hours | 4 | D 101 | 4％ | 1.6％ | 76％ | 6.4∶1 |
Embodiment six
| Material | Extract concentration | Extraction liquid | Alkali concn | Hydrolysis temperature | Hydrolysis time | PH value | Adsorption column | Active C | Yield | Total saponin content | The saponin(e ratio |
| Bud | 90％ | Sherwood oil | 2％ | 80℃ | 2 hours | 7 | AB-8 | 5％ | 1.7％ | 64％ | 8.7∶1 |
Embodiment seven
| Material | Extract concentration | Extraction liquid | Alkali concn | Hydrolysis temperature | Hydrolysis time | PH value | Adsorption column | Active C | Yield | Total saponin content | The saponin(e ratio |
| Bud | 80％ | Sherwood oil | 4％ | 100 ℃ | 2 hours | 7 | HPD1 00 | 4％ | 1.9％ | 69％ | 7.9∶1 |
Embodiment eight
| Material | Extract concentration | Extraction liquid | Alkali concn | Hydrolysis temperature | Hydrolysis time | PH value | Adsorption column | Active C | Yield | Total saponin content | The saponin(e ratio |
| Bud | 70％ | Sherwood oil | 6％ | 100 ℃ | 2 hours | 6 | HPD3 00 | 3％ | 2.0％ | 71％ | 7.5∶1 |
Embodiment nine
| Material | Extract concentration | Extraction liquid | Alkali concn | Hydrolysis temperature | Hydrolysis time | PH value | Adsorption column | Active C | Yield | Total saponin content | The saponin(e ratio |
| Bud | 60％ | Benzene | 10％ | 60℃ | 2 hours | 5 | Polymeric amide | 4％ | 1.7％ | 60％ | 6∶1 |
The inside and outside anti-tumor activity evaluation experimental of embodiment ten Lonicera macranthoides active total saponin extracts
1. Lonicera macranthoides active total saponin extract is to human liver cancer cell HepG
2And human lung cancer cell A549's restraining effect
1.1 purpose: the research Lonicera macranthoides active total saponin extract is to human liver cancer cell HepG
2And human lung cancer cell A549's growth in vitro restraining effect.
1.2 material: tetramethyl-azoles nitroblue (MTT); Lonicera macranthoides active total saponin extract: face with before being made into respective concentration; People's liver cancer HepG
2Cell strain or the strain of people's lung cancer A549 cell place the RPMI-1640 substratum that contains 10% calf serum, at 5%CO
2, go down to posterity in 37 ℃ the cell culture incubator stand-by.
1.3 method and result: people's liver cancer HepG that will be in logarithmic phase
2It is 2 * 10 that concentration is adjusted in cell strain or the strain of people's lung cancer A549 cell
5Ml
-1, cultivate after 24 hours, join 5 medicine groups respectively by listed drug level in the table, each drug level is all established 4 multiple holes, the calculating of averaging, other establishes a blank hole.Cell is at 37 ℃, 5%CO
2Continue under the condition to cultivate after 48 hours, add the MTT liquid 20M1 of 5mg/ml, continue to cultivate 4 hours again, add DMSO dissolving back and measure the OD value at the 570nm place with microplate reader rapidly, calculate inhibitory rate of cell growth, experimental result sees Table 1.
Growth inhibition ratio (%)=(1-dosing hole average A value/blank hole average A value) * 100%
Table 1 couple HepG
2The cytotoxicity of cell and A549 cell
Lonicera macranthoides active total saponin extract with different concns is handled HepG
2Cell and A549 cell, the growth of visible cancer cells all is suppressed, and is concentration and time-dependent manner.The result shows that Lonicera macranthoides active total saponin extract has stronger cytotoxicity to tumour cell.
2. Lonicera macranthoides active total saponin extract and the not comparative studies of hydrolysis total saponin extracts antitumour activity
2.1 purpose: relatively Lonicera macranthoides active total saponin extract and the not antitumour activity of hydrolysis total saponin extracts.
2.2 material: Lonicera macranthoides active total saponin extract: face with before being made into respective concentration; Hydrolysis total saponin extracts not: the largeflower-like honeysuckle flower bud is 90% extraction using alcohol with concentration, reclaims solvent, use sherwood oil, ethyl acetate extraction successively, water layer reclaims solvent to concentrated extract, adds acetone precipitation, and is centrifugal, precipitation is dissolved with rare alcohol, regulating pH value is 6, last D101 macroporous resin column, first water and 20% washing with alcohol post, use the 30%-90% ethanol elution again, elutriant decolouring, filtration, concentrate drying are promptly.
2.3 method and result: the MTT colorimetry is the same, is divided into blank group, active group and not hydrolysis group, and wherein for the hydrolysis component is five concentration groups, experimental result sees Table 2.
Table 2 Lonicera macranthoides active total saponin extract and the not comparison of the antitumour activity of hydrolysis total saponin extracts
From experimental result as can be seen, hydrolysis largeflower-like honeysuckle flower total saponine anti-tumor is not active reduces IC
50＞300 μ g/ml.Hydrolysis reaction has improved the anti-tumor activity of extract greatly.
3. Lonicera macranthoides active total saponin extract is to H
22The anti-tumor experiment of tumor-bearing mice
3.1 purpose: the research Lonicera macranthoides active total saponin extract is to rat liver cancer H
22Restraining effect.
3.2 material: 40 of Male Kunming strain mice, body weight (20 ± 2g); 5 FU 5 fluorouracil, the general medicine company product in the rising sun East Sea, Shanghai; Lonicera macranthoides active total saponin extract: face with preceding and be made into respective concentration with physiological saline.20 ± 3 ℃ of laboratory temperatures, relative humidity: 75%.
3.3 method and result: strip the liver cancer H that went down to posterity 10 days under the aseptic condition
22The cancer piece is made homogenate, and with physiological saline dilution in 1: 3, it is 2 * 10 that counting is adjusted cell concn
6L
-1Every 0.2ml, it is subcutaneous to be inoculated in the right armpit of mouse, be divided into 5 groups after 24 hours at random, promptly dosage group, medicine small dose group and positive controls (5 FU 5 fluorouracil) in negative control group (physiological saline), the heavy dose of group of medicine, the medicine are all irritated stomach respective concentration medicine or physiological saline for every group, once a day, the execution of weighing after ten days, the tumor mass calculating inhibition rate of tumor growth of weighing the results are shown in Table 3.
Inhibition rate of tumor growth inhibiting rate (%)=(it is heavy that the average knurl of average knurl weight/control group is organized in the 1-treatment) * 100%
Table 3 Lonicera macranthoides active total saponin is to H
22The influence of tumor-bearing mice and Lewis tumor-bearing mice tumour inhibiting rate
Lonicera macranthoides active total saponin is to H
22The influence of tumor-bearing mice lifetime the results are shown in Table 4.
Table 4 Lonicera macranthoides active total saponin is to H
22The influence of tumor-bearing mice lifetime
The result shows: sample sets and negative control group be the survival time of mice phenomenal growth relatively, highly significant difference is arranged, p＜0.01.
4. Lonicera macranthoides active total saponin extract is to the restraining effect of Mice Bearing Lewis Lung Cancer
4.1 purpose: the research Lonicera macranthoides active total saponin extract is to the restraining effect of Mice Bearing Lewis Lung Cancer.
4.2 material: 32 of Male Kunming strain mice, body weight (20 ± 2g); Lonicera macranthoides active total saponin extract: face with preceding and be made into respective concentration with physiological saline.20 ± 3 ℃ of laboratory temperatures, relative humidity: 75%.
4.3 method and result: strip the Lewis lung cancer cancer piece that went down to posterity 10 days under the aseptic condition, make homogenate, with physiological saline dilution in 1: 3, it is 1 * 10 that counting is adjusted cell concn
7Ml
-1, every 0.2ml, it is subcutaneous to be inoculated in the right armpit of mouse, be divided into 5 groups after 24 hours at random, promptly dosage group and medicine small dose group in negative control group (physiological saline), the heavy dose of group of medicine, the medicine are all irritated stomach respective concentration medicine or physiological saline for every group, once a day, the execution of weighing after ten days.Weighing tumor mass weight is calculated inhibition rate of tumor growth, sees Table 3.
Inhibition rate of tumor growth inhibiting rate (%)=(it is heavy that the average knurl of average knurl weight/control group is organized in the 1-treatment) * 100%
The result shows: Lonicera macranthoides active total saponin extract can significantly suppress H
22It is heavy that the tumor-bearing mice knurl heavily reaches Lewis tumor-bearing mice knurl, has antitumour activity.
Claims (4)
1. Lonicera macranthoides active total saponin extract, it is characterized in that total saponin content is 50%-90% in the extract, contained saponin component meets following general formula (1), wherein main contained saponin(e and their weight ratio is: Macranthoside B: Macranthoside A=12～6: 1
R
3＝H，OH
R
2＝H
R
1=H, sugar chain (1).
2. extract according to claim 1, it is characterized in that said extract is the extract that obtains by following method: the largeflower-like honeysuckle flower flower and alabastrum, with concentration is the extraction using alcohol of 50%-90%, reclaim solvent, with the low polar solvent extraction, water layer is used ethyl acetate extraction again, water layer reclaims solvent to concentrated extract, add 1%-10%NaOH or KOH solution, degraded 2-4 hour down for 40-100 ℃, cold back adds acetone precipitation, centrifugal, centrifugal gained precipitation washes with water to neutrality, and with rare alcohol dissolving, the adjusting pH value is 4-7, last macroporous resin column or polyamide column, elder generation's water and 20% washing with alcohol post are used the 30%-90% ethanol elution again, collect elutriant, the medical active carbon decoloring that adds 3%-5%, filter, concentrate drying promptly gets Lonicera macranthoides active total saponin.
3. extract according to claim 2, it is characterized in that using sherwood oil, gasoline, the benzene extraction, water layer is used ethyl acetate extraction again, water layer reclaims solvent to concentrated extract, add 1%-10%NaOH or KOH solution, degraded 2-4 hour down for 40-100 ℃, cold back adds acetone precipitation, and is centrifugal, and centrifugal gained precipitation washes with water to neutrality, with rare alcohol dissolving, the adjusting pH value is 4-7, mixes sample or directly goes up HP20, D101, AB-8, HPD100 or HPD300 type macroporous resin or directly go up polyamide column, first water and 20% washing with alcohol post, use the 30%-90% ethanol elution again, collect elutriant, add the medicinal granular active carbon decolouring of 3%-5%, filter, concentrate drying promptly gets Lonicera macranthoides active total saponin.
4. according to the application of the resulting extract of claim 1-3 in the medicine of preparation treatment or prevention human hepatocellular.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100392944A CN100408594C (en) | 2006-04-04 | 2006-04-04 | Lonicera macranthoides active total saponin extract and its preparing method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100392944A CN100408594C (en) | 2006-04-04 | 2006-04-04 | Lonicera macranthoides active total saponin extract and its preparing method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1821262A CN1821262A (en) | 2006-08-23 |
| CN100408594C true CN100408594C (en) | 2008-08-06 |
Family
ID=36922852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100392944A Expired - Fee Related CN100408594C (en) | 2006-04-04 | 2006-04-04 | Lonicera macranthoides active total saponin extract and its preparing method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100408594C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406509B (en) * | 2008-11-28 | 2011-08-31 | 江苏省中国科学院植物研究所 | Lonicera confusa extract and preparation method and application thereof |
| CN102408465B (en) * | 2011-09-23 | 2015-09-30 | 江苏省中国科学院植物研究所 | A kind of largeflower-like honeysuckle flower chlorogenic acid Ester Saponin and its production and use |
| CN103908482A (en) * | 2012-12-28 | 2014-07-09 | 中国医学科学院药用植物研究所 | Ethyl acetate extract of Lonicera macranthoides, preparation method and application thereof |
| CN105311085B (en) * | 2014-06-06 | 2020-01-14 | 天津药物研究院 | Leaf or flower extract of honeysuckle stem or its base plant honeysuckle, its preparation method and application |
| CN110403971A (en) * | 2018-04-26 | 2019-11-05 | 胤安国际（辽宁）基因科技股份有限公司 | A kind of extracting method and its application of honeysuckle extract |
| CN109678922B (en) * | 2018-11-12 | 2020-07-14 | 广州市香雪制药股份有限公司 | Nortriterpenoid compound and preparation method and application thereof |
-
2006
- 2006-04-04 CN CNB2006100392944A patent/CN100408594C/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 灰毡毛忍冬化学成分的研究. 茅青等.药学学报，第28卷第4期. 1993 |
| 灰毡毛忍冬化学成分的研究. 茅青等.药学学报，第28卷第4期. 1993 * |
| 灰毡毛忍冬花蕾中的化学成分. 许小方等.中国天然药物，第4卷第1期. 2006 |
| 灰毡毛忍冬花蕾中的化学成分. 许小方等.中国天然药物，第4卷第1期. 2006 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1821262A (en) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nie et al. | A review on the isolation and structure of tea polysaccharides and their bioactivities | |
| ES2543981T3 (en) | Purification of elagitannins | |
| CN101904880B (en) | Mangosteen total xanthone extract and application thereof in preparation of TR3 receptor inducer | |
| CN101863871B (en) | Total glycosides of Rhodiola rosea, medical application and preparation method thereof | |
| CN100408594C (en) | Lonicera macranthoides active total saponin extract and its preparing method and use | |
| CN104825500B (en) | Ganoderma leucocontextum extract, extraction method and application thereof | |
| Yang et al. | Enhanced oral bioavailability and prophylactic effects on oxidative stress and hepatic damage of an oil solution containing a rosmarinic acid–phospholipid complex | |
| CN106389453B (en) | Flavone glycoside composition | |
| Preethi et al. | Screening of natural polysaccharides extracted from the fruits of Pithecellobium dulce as a pharmaceutical adjuvant | |
| Sun et al. | Anti-tumor and immunomodulation activity of polysaccharides from Dendrobium officinale in S180 tumor-bearing mice | |
| CN101229335B (en) | Enzyme method for preparing smilax scobinicaulis total saponin extract | |
| Liang et al. | Physalis alkekengi L. var. franchetii (Mast.) Makino: A review of the pharmacognosy, chemical constituents, pharmacological effects, quality control, and applications | |
| CN105017345B (en) | The method of four kinds of compounds of extraction and the application simultaneously from selfheal | |
| Lenchyk | Determination of phenolic compounds in prunus domestica leaves extract | |
| CN104189086B (en) | Preparation method and application of lupulus natural pharmaceutical composition | |
| EP3281945B1 (en) | Phillygenin glucuronic acid derivative, preparation method and application thereof | |
| Kerbab et al. | Halimium halimifolium: From the chemical and functional characterization to a nutraceutical ingredient design | |
| CN102133220B (en) | Preparation method of pulsatilla saponin A | |
| CN105267356B (en) | A kind of morinda root oligosacchride and preparation method thereof | |
| CN102219782B (en) | Method for extracting and separating viterxin and isovitexin from natural product | |
| CN101085804A (en) | Method for preparing lonicera macranthoides hypo-saponin B and application of the same in curing liver cancer, breast carcinoma and cervical cancer | |
| CN102295678B (en) | Purpose of triterpenoid-saponin compound extracted form anemone taipaiensis | |
| Upyr et al. | Study of biologically active compounds in Prunus persica leaves extract | |
| CN103169724A (en) | Preparation method and application of oleanolic acid trisaccharide saponin component | |
| CN109748945A (en) | Four kinds of Gypenoside L and Gypenoside LI acetyl derivatives and its purposes for preparing anti-tumor drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080806 Termination date: 20130404 |